4:47 PM
 | 
Jun 03, 2014
 |  BC Extra  |  Top Story

Teva to acquire migraine play Labrys

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will acquire Labrys Biologics Inc. (San Mateo, Calif.) for $200 million in cash up front plus up to $625 million in developmental milestones. Labrys' sole compound is LBR-101,...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >